BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 16174072)

  • 1. Distribution of the heterogeneity of des-gamma-carboxyprothrombin in patients with hepatocellular carcinoma.
    Uehara S; Gotoh K; Handa H; Tomita H; Senshuu M
    J Gastroenterol Hepatol; 2005 Oct; 20(10):1545-52. PubMed ID: 16174072
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The des-gamma-carboxy prothrombin index is a new prognostic indicator for hepatocellular carcinoma.
    Nagaoka S; Yatsuhashi H; Hamada H; Yano K; Matsumoto T; Daikoku M; Arisawa K; Ishibashi H; Koga M; Sata M; Yano M
    Cancer; 2003 Dec; 98(12):2671-7. PubMed ID: 14669288
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Des-gamma-carboxy prothrombin (DCP) ratio is a useful prognostic tumor marker for single nodule hepatocellular carcinoma (HCC).
    Murakami N; Tamano M; Yoneda M; Sugaya H; Hiraishi H
    Hepatogastroenterology; 2008; 55(81):197-201. PubMed ID: 18507106
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Des-gamma-carboxyprothrombin, alpha-fetoprotein and AFP-L3 in patients with chronic hepatitis, cirrhosis and hepatocellular carcinoma.
    Durazo FA; Blatt LM; Corey WG; Lin JH; Han S; Saab S; Busuttil RW; Tong MJ
    J Gastroenterol Hepatol; 2008 Oct; 23(10):1541-8. PubMed ID: 18422961
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Serum des-gamma-carboxyprothrombin level by a modified enzyme immunoassay method in hepatocellular carcinoma: clinical significance in small hepatocellular carcinoma.
    Soga K; Watanabe T; Aikawa K; Toshima M; Shibasaki K; Aoyagi Y
    Hepatogastroenterology; 1998; 45(23):1737-41. PubMed ID: 9840138
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Des-gamma carboxyprothrombin can differentiate hepatocellular carcinoma from nonmalignant chronic liver disease in american patients.
    Marrero JA; Su GL; Wei W; Emick D; Conjeevaram HS; Fontana RJ; Lok AS
    Hepatology; 2003 May; 37(5):1114-21. PubMed ID: 12717392
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tumour-specific induction of immune complexes: DCP-IgM in hepatocellular carcinoma.
    Beneduce L; Pesce G; Gallotta A; Zampieri F; Biasiolo A; Tono N; Boscato N; Gatta A; Pontisso P; Fassina G
    Eur J Clin Invest; 2008 Aug; 38(8):571-7. PubMed ID: 18625005
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Determination of serum des-gamma-carboxy prothrombin levels in patients with small-sized hepatocellular carcinoma: comparison of the conventional enzyme immunoassay and two modified methods.
    Nomura F; Ishijima M; Horikoshi A; Nakai T; Ohnishi K
    Am J Gastroenterol; 1996 Jul; 91(7):1380-3. PubMed ID: 8677999
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Measurement of serum levels of des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma by a revised enzyme immunoassay kit with increased sensitivity.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Watanabe K; Magario N; Yokoo T; Naraki T
    Cancer; 1999 Feb; 85(4):812-8. PubMed ID: 10091758
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sensitivity and specificity of des-gamma-carboxy prothrombin for diagnosis of patients with hepatocellular carcinomas varies according to tumor size.
    Nakamura S; Nouso K; Sakaguchi K; Ito YM; Ohashi Y; Kobayashi Y; Toshikuni N; Tanaka H; Miyake Y; Matsumoto E; Shiratori Y
    Am J Gastroenterol; 2006 Sep; 101(9):2038-43. PubMed ID: 16848811
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sequential fluctuation pattern of serum des-gamma-carboxy prothrombin levels detected by high-sensitive electrochemiluminescence system as an early predictive marker for hepatocellular carcinoma in patients with cirrhosis.
    Shimizu A; Shiraki K; Ito T; Sugimoto K; Sakai T; Ohmori S; Murata K; Takase K; Tameda Y; Nakano T
    Int J Mol Med; 2002 Mar; 9(3):245-50. PubMed ID: 11836630
    [TBL] [Abstract][Full Text] [Related]  

  • 12. gamma-Carboxyglutamic acid content of hepatocellular carcinoma-associated des-gamma-carboxy prothrombin.
    Naraki T; Kohno N; Saito H; Fujimoto Y; Ohhira M; Morita T; Kohgo Y
    Biochim Biophys Acta; 2002 Apr; 1586(3):287-98. PubMed ID: 11997080
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Serum levels of des-gamma-carboxy prothrombin measured using the revised enzyme immunoassay kit with increased sensitivity in relation to clinicopathologic features of solitary hepatocellular carcinoma.
    Okuda H; Nakanishi T; Takatsu K; Saito A; Hayashi N; Takasaki K; Takenami K; Yamamoto M; Nakano M
    Cancer; 2000 Feb; 88(3):544-9. PubMed ID: 10649245
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A study about mechanisms of des-gamma-carboxy prothrombin's production in hepatocellular carcinoma.
    Bertino G; Ardiri AM; Boemi PM; Ierna D; Interlandi D; Caruso L; Minona E; Trovato MA; Vicari S; Li Destri G; Puleo S
    Panminerva Med; 2008 Sep; 50(3):221-6. PubMed ID: 18927526
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Measurement of serum and tissue des-gamma-carboxyprothrombin in resectable hepatocellular carcinoma.
    Xiang CH; Zhang W; Inagaki Y; Zhang KM; Nakano Y; Kokudo N; Sugawara Y; Dong JH; Nakata M; Tang W
    Anticancer Res; 2008; 28(4B):2219-24. PubMed ID: 18751398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Assay of des-gamma-carboxyprothrombin using staphylocoagulase. Application to the diagnosis of cellular hepatocarcinoma.
    Soulier JP; Gozin D; Lefrère JJ
    Haematologia (Budap); 1986; 19(1):3-12. PubMed ID: 2424813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of serum PIVKA-II (DCP) determination for differentiation between benign and malignant liver diseases.
    Lamerz R; Runge M; Stieber P; Meissner E
    Anticancer Res; 1999; 19(4A):2489-93. PubMed ID: 10470180
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Significance of alpha-fetoprotein and des-gamma-carboxy prothrombin in patients with hepatocellular carcinoma undergoing hepatectomy.
    Yamamoto K; Imamura H; Matsuyama Y; Hasegawa K; Beck Y; Sugawara Y; Makuuchi M; Kokudo N
    Ann Surg Oncol; 2009 Oct; 16(10):2795-804. PubMed ID: 19669841
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Utility of Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein and des-gamma-carboxy prothrombin, alone or in combination, as biomarkers for hepatocellular carcinoma.
    Sterling RK; Jeffers L; Gordon F; Venook AP; Reddy KR; Satomura S; Kanke F; Schwartz ME; Sherman M
    Clin Gastroenterol Hepatol; 2009 Jan; 7(1):104-13. PubMed ID: 18849011
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Des-gamma-carboxyprothrombin expression in cancer and/or non-cancer liver tissues: association with survival of patients with resectable hepatocellular carcinoma.
    Tang W; Kokudo N; Sugawara Y; Guo Q; Imamura H; Sano K; Karako H; Qu X; Nakata M; Makuuchi M
    Oncol Rep; 2005 Jan; 13(1):25-30. PubMed ID: 15583797
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.